Milestone Scientific Inc. (MLSS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Milestone Scientific Inc. (MLSS) Healthcare & Pipeline Overview

Milestone Scientific Inc. focuses on innovative injection technologies for medical and dental markets, offering solutions like the CompuDent and CompuFlo systems. With a presence in the US, China, and internationally, the company targets improved drug delivery and patient comfort, but faces challenges in profitability and market penetration.

What Is the Investment Thesis for MLSS?

Milestone Scientific Inc. presents a speculative investment opportunity within the medical device sector. The company's innovative injection technologies, particularly the CompuFlo and STA systems, address a need for more precise and comfortable drug delivery. However, the company's negative profit margin of -63.8% raises concerns about its financial sustainability. Growth catalysts include expanding applications of the CompuFlo system in medical procedures and increasing adoption of the STA system in dental practices. Successful penetration into the Chinese market could also drive revenue growth. The investment thesis hinges on Milestone Scientific's ability to achieve profitability through increased sales and efficient cost management. A beta of 0.85 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

MLSS Key Highlights

Market capitalization of $38.4M indicates a small-cap company with potential for growth but also higher risk.

• Gross margin of 71.4% demonstrates strong pricing power and efficient production of its injection technologies.
• Negative profit margin of -63.8% highlights the company's struggle to achieve profitability despite high gross margins.
• Beta of 0.85 suggests the stock is less volatile than the overall market, potentially offering some downside protection.
• The company operates in both Dental and Medical segments, diversifying its revenue streams across different healthcare applications.

Who Are MLSS's Competitors?

MLSS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MLSS's Key Strengths?

Innovative computer-controlled injection technology.

• Strong gross margin indicating pricing power.
• Established presence in the dental anesthesia market.
• Proprietary technology protected by patents.

What Are MLSS's Weaknesses?

Negative profit margin indicating financial challenges.

• Small market capitalization limiting access to capital.
• Concentrated product line with reliance on injection technologies.
• Limited brand awareness in the broader medical market.

What Could Drive MLSS Stock Higher?

Regulatory approvals for new applications of the CompuFlo system.

• Increased adoption of the STA system in dental practices.
• Expansion of the sales and distribution network in China.
• Potential strategic partnerships with other medical device companies.

What Are the Key Risks for MLSS?

Financial-distress signal — its Altman Z-Score of -18.16 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Regulatory hurdles and approval processes.
• Technological obsolescence.
• Negative profit margin and financial challenges.
• Economic downturn affecting healthcare spending.

What Are the Growth Opportunities for MLSS?

• Expansion into New Medical Applications: Milestone Scientific has the opportunity to expand the use of its CompuFlo system into new medical specialties, such as dermatology and podiatry. The market for minimally invasive procedures in these areas is growing, driven by patient demand for less painful and more convenient treatments. By targeting these new applications, Milestone Scientific can increase its revenue streams and diversify its customer base. Success in this area depends on demonstrating the clinical benefits of CompuFlo in these new settings and securing regulatory approvals where necessary. The timeline for this expansion is estimated at 2-3 years.
• Increased Adoption in Dental Practices: The STA Single Tooth Anesthesia System offers a compelling alternative to traditional dental injections, promising greater precision and reduced patient anxiety. By increasing adoption among dental practitioners, Milestone Scientific can significantly boost its sales. This requires effective marketing and training programs to educate dentists about the benefits of the STA system and overcome any resistance to change. The dental anesthesia market is substantial, and capturing a larger share of this market represents a significant growth opportunity. This expansion could be realized within the next 2 years.
• Penetration of the Chinese Market: China represents a significant growth opportunity for Milestone Scientific, given its large and growing healthcare market. The company can leverage its existing presence in China to expand its sales and distribution network. This requires adapting its products and marketing strategies to the specific needs of the Chinese market, as well as navigating the regulatory landscape. Success in China could significantly increase Milestone Scientific's revenue and profitability. This market penetration is an ongoing opportunity with potential for significant gains over the next 3-5 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with other medical device companies or healthcare providers can accelerate Milestone Scientific's growth. These partnerships can provide access to new markets, technologies, and distribution channels. For example, collaborating with a leading dental supply company could significantly increase the reach of the STA system. Identifying and securing these partnerships is a key priority for Milestone Scientific. These partnerships could materialize within the next 1-2 years.
• Development of New Injection Technologies: Investing in research and development to create new and improved injection technologies can drive long-term growth. This includes exploring new applications for its existing technologies, as well as developing entirely new products. By staying at the forefront of innovation, Milestone Scientific can maintain its competitive advantage and capture new market opportunities. This requires a sustained commitment to R&D and a focus on addressing unmet needs in the healthcare market. The timeline for developing and commercializing new technologies is typically 3-5 years.

What Are MLSS's Competitive Advantages?

• Proprietary computer-controlled injection technology.
• Established brand recognition in the dental anesthesia market.
• Patents protecting its key innovations.
• Specialized expertise in drug delivery systems.

What Does MLSS Do?

Milestone Scientific Inc., founded in 1989 and headquartered in Roseland, New Jersey, operates within the healthcare sector, specifically focusing on the design, development, and commercialization of advanced injection technologies and devices. The company's core business revolves around creating solutions for medical, dental, and cosmetic applications, with a geographic presence spanning the United States, China, and other international markets. Milestone Scientific operates through two primary segments: Dental and Medical. In the dental segment, the company's flagship products include the CompuDent and STA Single Tooth Anesthesia System. These systems are designed to provide precise and controlled local anesthetic delivery for various dental procedures, aiming to reduce patient discomfort and improve clinical outcomes. The medical segment features the CompuFlo system, a computer-controlled drug delivery system used for painless administration of drugs, anesthetics, and other medicaments. This system also supports aspiration of bodily fluids or previously injected substances. The CompuFlo Epidural system is tailored for epidural anesthesia applications. Additionally, the company offers CompuMed, which is used in plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, orthopedics, and other disciplines. Milestone Scientific's products are characterized by their computer-controlled precision and focus on minimizing patient discomfort during injections. The company continues to refine its technology to expand its applications and market reach within the medical and dental fields.

What Products and Services Does MLSS Offer?

• Designs and develops computer-controlled injection technologies.
• Commercializes these technologies for medical, dental, and cosmetic applications.
• Offers the CompuDent and STA systems for precise dental anesthesia.
• Provides the CompuFlo system for painless drug delivery in medical procedures.
• Targets improved precision and reduced patient discomfort during injections.
• Operates in the United States, China, and internationally.
• Serves both the dental and medical markets with specialized injection solutions.

How Does MLSS Make Money?

• Sells CompuDent and STA systems to dental practices.
• Sells CompuFlo systems to hospitals and medical clinics.
• Generates revenue from disposable handpieces and other consumables.
• Expands market reach through distributors and direct sales.

What Industry Does MLSS Operate In?

Milestone Scientific operates in the medical instruments and supplies industry, a segment driven by technological advancements and increasing demand for minimally invasive procedures. The global medical device market is projected to reach significant growth in the coming years, fueled by an aging population and rising healthcare expenditures. Competition includes established players and smaller innovators. Milestone Scientific differentiates itself through its computer-controlled injection technology, targeting improved precision and patient comfort. The company's success depends on its ability to gain market share in a competitive landscape and demonstrate the clinical and economic benefits of its products.

Who Are MLSS's Key Customers?

• Dental practitioners seeking precise anesthesia delivery.
• Hospitals and medical clinics requiring controlled drug delivery systems.
• Cosmetic surgeons and dermatologists using injection technologies.
• Patients benefiting from reduced pain and anxiety during injections.

Milestone Scientific Inc. (MLSS) Valuation Context

Valued at $38.4M, MLSS is classified as a micro-cap stock. Analyst price targets span from $1.00 to $1.00, with a consensus of $1.00. At the current price of $0.43, that implies approximately 130% upside potential. Relative to its peer group, MLSS's quantitative score of 23/100 is below the peer average of 43/100.

MLSS Revenue & Earnings Trend

In Q2 FY2026, MLSS generated $2.8M in top-line revenue, marking a sequential increase of 31.4%. The company recorded a net loss of $1.1M, with diluted EPS of $-0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, MLSS averaged $-0.01 in diluted EPS.

Company Profile

Milestone Scientific Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Roseland, US. The company is led by CEO Eric C. Hines. MLSS has traded publicly since 1995.

Key Financial Metrics

Return on assets is -57.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.8%, the inverse of the P/E and a quick read on earnings relative to price.

Milestone Scientific Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -18.16 places it in the distress zone, a signal of elevated financial risk.

Milestone Scientific Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 52.7% below estimates on average.

The most recent 12 insider filings for Milestone Scientific Inc. break down as 12 sales and 0 purchases. On net that is roughly 368K shares disposed (about $168K), a signal worth weighing alongside the fundamentals.

MLSS Financials

MLSS Latest News

MLSS Analyst Consensus

MLSS MoonshotScore

What Investors Ask About Milestone Scientific Inc. (MLSS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources